Anidulafungin

Anidulafungin

File:Anidulafungin.svg
Clinical data
ATC code	J02AX06 (WHO)
Pharmacokinetic data
Protein binding	84%
Elimination half-life	40-50 hours
Identifiers
CAS Number	166663-25-8
PubChem CID	166548
DrugBank	APRD01301
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C58H73N7O17
Molar mass	1140.24 g/mol

Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006 [1]; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of anti-fungal drugs known as the echinocandins: its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.

References

• Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T (2004). "Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia". Antimicrob Agents Chemother. 48 (6): 2021&ndash, 4.CS1 maint: Multiple names: authors list (link)
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005). "In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole". J Clin Microbiol. 43 (11): 5425&ndash, 7.CS1 maint: Multiple names: authors list (link)
• Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP (2005). "Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis". Antimicrob Agents Chemother. 49 (11): 4795&ndash, 7.CS1 maint: Multiple names: authors list (link)